<DOC>
	<DOCNO>NCT02734615</DOCNO>
	<brief_summary>To characterize safety tolerability , identify recommended dos regimens future study , pharmacokinetics ( PK ) , pharmacodynamics ( PD ) anti-tumor activity LSZ102 single agent combination either LEE011 BYL719 adult patient locally advance metastatic ER+ breast cancer progress endocrine therapy .</brief_summary>
	<brief_title>Phase I/Ib Trial LSZ102 Single Agent LSZ102 + LEE011 LSZ102 + BYL719 ER+ Breast Cancers</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Written informed consent must obtain prior procedure Histologically and/or cytologically confirm diagnosis ER+ breast cancer Advanced metastatic breast cancer Objective evidence either progression endocrine therapy metastatic locally advanced disease OR recurrence , within 12 month end adjuvant treatment letrozole anastrozole Must able swallow tablet capsule Symptomatic CNS metastases Patients whose laboratory value meet protocol criterion Clinically significant cardiac disease Impaired gastrointestinal function ( GI ) GI disease may significantly alter absorption oral medication Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>LSZ102</keyword>
	<keyword>ER+ breast cancer</keyword>
	<keyword>advanced ER+ breast cancer</keyword>
	<keyword>metastatic ER+ breast cancer</keyword>
	<keyword>SERD</keyword>
	<keyword>SERM</keyword>
	<keyword>fulvestrant</keyword>
	<keyword>tamoxifen</keyword>
	<keyword>aromatase inhibitor</keyword>
	<keyword>ESR1</keyword>
	<keyword>estrogen receptor</keyword>
	<keyword>endocrine therapy</keyword>
</DOC>